These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27552207)

  • 1. Lifitegrast (Xiidra) for dry eye disease.
    Med Lett Drugs Ther; 2016 Aug; 58(1502):110-1. PubMed ID: 27552207
    [No Abstract]   [Full Text] [Related]  

  • 2. Lifitegrast for the treatment of dry eye disease in adults.
    Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
    Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease.
    Patel J; Franko J
    Am Fam Physician; 2018 Jul; 98(2):119-120. PubMed ID: 30215991
    [No Abstract]   [Full Text] [Related]  

  • 5. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
    Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
    Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
    Paton DM
    Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program.
    Chan CC; Prokopich CL
    J Pharm Pharm Sci; 2019; 22(1):49-56. PubMed ID: 30636670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
    Tong AY; Passi SF; Gupta PK
    Eye Contact Lens; 2020 Jan; 46 Suppl 1():S20-S24. PubMed ID: 30985492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifitegrast, Bezlotoxumab, and Sugammadex sodium.
    Hussar DA; Cheeseman RS
    J Am Pharm Assoc (2003); 2017; 57(2):284-287. PubMed ID: 28285777
    [No Abstract]   [Full Text] [Related]  

  • 14. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
    Periman LM; Perez VL; Saban DR; Lin MC; Neri P
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry Eye Syndrome Preferred Practice Pattern®.
    Akpek EK; Amescua G; Farid M; Garcia-Ferrer FJ; Lin A; Rhee MK; Varu DM; Musch DC; Dunn SP; Mah FS;
    Ophthalmology; 2019 Jan; 126(1):P286-P334. PubMed ID: 30366798
    [No Abstract]   [Full Text] [Related]  

  • 16. A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
    Nichols KK; Evans DG; Karpecki PM
    Curr Eye Res; 2021 May; 46(5):609-614. PubMed ID: 33238774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs.
    Chung JK; Spencer E; Hunt M; McCauley T; Welty D
    J Ocul Pharmacol Ther; 2018; 34(1-2):224-232. PubMed ID: 29267138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.
    Guimaraes de Souza R; Yu Z; Stern ME; Pflugfelder SC; de Paiva CS
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):543-549. PubMed ID: 29958030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restasis use in the chronic dry eye patient.
    Bataoel A
    Insight; 2007; 32(3):21. PubMed ID: 17953324
    [No Abstract]   [Full Text] [Related]  

  • 20. 2017 New Drug Update.
    Hussar DA; Finn LA
    Consult Pharm; 2017 May; 32(5):258-268. PubMed ID: 28483006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.